ARWR
ArrowheadANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The primary-source picture is still constructive: REDEMPLO is already approved in the U.S., China, Canada, and Australia, the EU decision is pending in Q2 2026, the balance sheet was materially reinforced, and the latest 10-Q also disclosed the Madrigal ARO-PNPLA3 license with $25 million upfront and up to $975 million in milestones plus royalties [#10-Q-2026-05-07]. That combination supports a multi-asset optionality argument rather than a one-product story.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -3.3.
What can break
Arrowhead's revenue base is still lumpy and partnership-driven; the latest quarter showed a sharp year-over-year revenue decline alongside a sizable operating loss [#10-Q-2026-05-07].
Momentum
86
Value
57
Sentiment
63
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $82.00 · Bull $96.00 · Bear $60.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-16 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $81.70
Why
Momentum86 · Δ7d -3.3
Value57 · Δ7d +0.2
Sentiment63 · Δ7d +2.8
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
86
34% active weight
Current posture
7d trendSoftening
Δ7d
-3.3
Δ21d
-6.8
Value
57
32% active weight
Current posture
7d trendFlat
Δ7d
+0.2
Δ21d
+0.5
Sentiment
63
33% active weight
Current posture
7d trendImproving
Δ7d
+2.8
Δ21d
+11.7
Why this grade
Composite grade A. Momentum 85.6 / Value 57.0 / Sentiment 63.0
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$10.59B
Beta
1.22
Shares Out
135.81M
P/E (TTM) · Derived
-7799.5
P/S (TTM)
10.46
P/FCF (TTM)
55.30
Rev YoY
-29.6%
EPS YoY
+87.4%
Gross Margin
-
Op Margin
+11.9%
Net Debt
-$295.19M
Current Ratio
4.86
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology